APA (7th ed.) Citation

Zhao, M., Ma, L., Duan, X., Huo, Y., Liu, S., Zhao, C., . . . Li, M. (2024). Tofacitinib versus thalidomide for mucocutaneous lesions of systemic lupus erythematosus: A real-world CSTAR cohort study XXVII. Lupus, 33(10), 1109-1115. https://doi.org/10.1177/09612033241272953

Chicago Style (17th ed.) Citation

Zhao, Man, et al. "Tofacitinib Versus Thalidomide for Mucocutaneous Lesions of Systemic Lupus Erythematosus: A Real-world CSTAR Cohort Study XXVII." Lupus 33, no. 10 (2024): 1109-1115. https://doi.org/10.1177/09612033241272953.

MLA (9th ed.) Citation

Zhao, Man, et al. "Tofacitinib Versus Thalidomide for Mucocutaneous Lesions of Systemic Lupus Erythematosus: A Real-world CSTAR Cohort Study XXVII." Lupus, vol. 33, no. 10, 2024, pp. 1109-1115, https://doi.org/10.1177/09612033241272953.